Novo Nordisk's Weight-Loss Drug Struggles

Novo Nordisk, the pharmaceutical giant behind Wegovy, has seen a significant drop in share value this year, losing over fifty percent. The company faces disappointing trial results, competition, and concerns from investors. However, hopes remain for new developments, including a higher-dose Wegovy injection and an oral version, which could help compete with rivals like Eli Lilly. The success of these new products will depend on pricing, availability, and a head-to-head trial in 2026. Despite current challenges, many analysts remain positive about Novo Nordisks long-term prospects.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.